PrEP, or pre-exposure prophylaxis, is a medical approach to preventing HIV infection.
It involves using specific medications before potential exposure to HIV to reduce the likelihood of acquiring the virus. A PrEP essentials guide to understanding HIV prevention and medication use explains how this approach works, who may benefit from it, and why medical assessment and ongoing monitoring are important.
HIV is a virus that attacks the immune system, particularly CD4 cells, which help the body fight infections. It can be transmitted through certain bodily fluids, including blood, semen, vaginal fluids, rectal fluids, and breast milk. HIV is not transmitted through everyday contact such as hugging, sharing food, or using the same toilet.
PrEP was developed as part of broader HIV prevention efforts that include condoms, testing, and other measures. It is intended for people who do not have HIV but may have a possibility of exposure. PrEP differs from post-exposure prophylaxis (PEP), which is an emergency medication approach started after a possible exposure to HIV.
PrEP medications prevent HIV from establishing an infection when the virus enters the body. Depending on the medication, they interfere with processes the virus needs to reproduce inside human cells. When used according to the prescribed regimen, PrEP substantially reduces the likelihood of acquiring HIV through the routes it is designed to protect against.
PrEP is available in different forms, including oral medications and long-acting injections in countries where these have been approved. The appropriate option depends on local approval, individual health circumstances, exposure patterns, and clinical guidance.
PrEP does not treat an existing HIV infection. HIV testing is therefore essential before starting and during continued use, following the recommended clinical schedule.
PrEP may be relevant to people whose circumstances involve a possibility of HIV exposure. This can include people who have sexual partners with HIV whose viral suppression status is unknown or not consistently maintained, people who do not consistently use condoms in situations involving potential exposure, and people who share injection equipment.
A person's circumstances can change over time, so the decision to use PrEP can be revisited. A healthcare professional can help assess individual exposure patterns, medication options, and relevant health considerations without making assumptions about someone's identity or relationships.
HIV prevention involves several complementary approaches because no single method addresses every possible exposure. PrEP provides an additional option for people who may face ongoing exposure, while HIV testing helps identify infections and supports timely treatment.
Understanding PrEP also helps distinguish HIV prevention from the prevention of other sexually transmitted infections. PrEP does not prevent infections such as syphilis, gonorrhea, or chlamydia, and it does not prevent pregnancy. Other preventive measures may still be relevant depending on individual circumstances.
PrEP is highly effective against HIV when taken or administered according to the prescribed schedule. Protection depends on the medication type, how consistently it is used, and the route of exposure. Oral PrEP does not reach protective levels equally quickly in every tissue, so the timing of starting and stopping medication matters.
| Prevention approach | Main purpose | Important consideration |
|---|---|---|
| Oral PrEP | Reduces the likelihood of acquiring HIV | Requires adherence to the prescribed schedule |
| Long-acting injectable PrEP | Provides HIV prevention through scheduled injections | Follow-up appointments and injection timing matter |
| Condoms | Reduce the risk of HIV and several other sexually transmitted infections | Protection depends on correct and consistent use |
| HIV testing | Identifies HIV infection | Testing frequency depends on exposure and clinical guidance |
| PEP | Addresses a possible recent HIV exposure | Must be started as soon as possible, within 72 hours |
These approaches can complement one another. PEP is particularly time-sensitive: after a possible exposure, urgent medical assessment is important because treatment should begin as soon as possible and no later than 72 hours after exposure.
Before PrEP begins, a healthcare professional generally confirms HIV-negative status and reviews relevant medical history. Depending on the medication and individual circumstances, assessment may include kidney function, hepatitis screening, pregnancy considerations, and testing for other sexually transmitted infections.
Monitoring continues during PrEP use. Repeat HIV testing helps detect infection, while other tests may be needed to check medication safety or identify infections that require treatment. The specific schedule varies by medication, health history, and national guidelines.
Some people experience temporary effects such as nausea, headache, or stomach discomfort when starting oral PrEP. The type and likelihood of side effects vary by medication, and some people experience none. Certain oral medications can affect kidney function or bone health, making appropriate assessment important.
Long-acting injections can cause reactions at the injection site, such as pain or swelling. Anyone experiencing concerning symptoms should seek medical guidance rather than changing a prescribed regimen independently. PrEP is not appropriate for treating HIV, and taking it without appropriate testing can complicate the recognition and management of an infection.
<WritingBlock id="73184" variant="document">## Recent Updates
HIV prevention guidance continues to evolve as researchers evaluate additional medication options, testing approaches, and ways to support consistent protection. Recent developments have expanded the range of PrEP methods under consideration and increased attention to long-acting prevention.
A significant development in 2025 was the introduction of injectable lenacapavir as an additional HIV prevention option in the United States. The World Health Organization (WHO) also recommended twice-yearly injectable lenacapavir as an additional PrEP choice, alongside other established prevention methods. Availability and approval vary between countries, so local clinical guidance remains important. <Link url="https://www.who.int/news/item/14-07-2025-who-recommends-injectable-lenacapavir-for-hiv-prevention" title="WHO guidance on injectable lenacapavir"/>.
Long-acting medication may suit people who find daily tablets difficult to maintain. However, injections require scheduled administration, appropriate HIV testing, and follow-up. Oral PrEP remains an established option, and the choice between methods depends on individual circumstances and local availability.
Recent guidance also emphasizes appropriate HIV testing before and during long-acting PrEP use. Testing procedures help identify infections that may not be apparent from symptoms alone and support decisions about whether prevention medication should be continued. <Link url="https://www.cdc.gov/hivnexus/hcp/prep/index.html" title="CDC clinical guidance for PrEP"/>.
Research continues into how prevention methods can be integrated with routine healthcare and community-based testing. These developments aim to make HIV prevention more adaptable while maintaining attention to medication safety and accurate diagnosis.
Reliable educational resources can help explain PrEP eligibility, medication schedules, testing requirements, and the differences between prevention methods. Because recommendations and medication approvals vary by location, resources from recognized public health organizations are particularly useful.
The following resources provide general information about PrEP and HIV prevention:
World Health Organization (WHO): Publishes international HIV prevention recommendations and guidance on long-acting PrEP.
Centers for Disease Control and Prevention (CDC): Provides explanations of PrEP, testing, medication use, and clinical monitoring.
UNAIDS: Publishes global information about HIV prevention policies, treatment, and public health developments.
National health authorities: Provide locally relevant information about approved medications, eligibility, and access to HIV testing.
Medication schedules and appointment reminders can help people keep track of oral doses, injection visits, and follow-up testing. A personal record of test dates, prescribed medications, and questions for a healthcare professional can also support informed discussions.
Online risk-assessment tools may provide general information, but they cannot diagnose HIV or replace an appropriate clinical assessment. Anyone concerned about a recent possible exposure should seek urgent medical advice rather than relying on an online calculator.
PrEP is medication taken before potential exposure to HIV to reduce the likelihood of infection. It interferes with the processes HIV needs to establish itself in the body when used according to the prescribed regimen.
PrEP is highly effective when used as prescribed. Its effectiveness depends on the medication, consistency of use, and exposure route, and it does not prevent every sexually transmitted infection.
Oral PrEP involves taking medication according to a prescribed schedule, while injectable PrEP provides protection through scheduled injections. Availability, dosing intervals, and monitoring requirements depend on the medication and country.
HIV testing is essential before starting PrEP. Depending on the medication and personal health circumstances, assessment may also include kidney function, hepatitis screening, and tests for other sexually transmitted infections.
Seek urgent medical assessment for post-exposure prophylaxis (PEP). It should be started as soon as possible and within 72 hours of a possible exposure; PrEP is not a substitute for emergency PEP assessment.
PrEP is an important component of HIV prevention that includes oral medications and, in some locations, long-acting injections. Its effectiveness depends on the appropriate medication, correct use, and continued HIV testing and clinical monitoring. Developments in long-acting prevention are expanding the range of available approaches, although local access and recommendations differ. Understanding these principles helps explain how PrEP fits into broader HIV prevention efforts.
By: Amelia
Updated: October 19, 2026
Read More
By: Milano
Updated: October 07, 2026
Read More
By: Amelia
Updated: October 19, 2026
Read More
By: Amelia
Updated: October 19, 2026
Read More